Pre-Market Breakdown: Galena Biopharma Inc., Novavax Inc., Ariad Pharma Inc., and MannKind Corp. PR Newswire LONDON, November 27, 2013 LONDON, November 27, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Tuesday, November 26, 2013, the U.S. equity market ended on a higher note. The S&P 500 and the NASDAQ Composite gained 0.01% and 0.58%, respectively, while the Dow Jones Industrial Average ended flat. Shares in the biotechnology industry were mostly in the black as the broader market posted gains. The major movers in the industry included Galena Biopharma Inc. (NASDAQ: GALE), Novavax Inc. (NASDAQ: NVAX), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), and MannKind Corporation (NASDAQ: MNKD). All these companies are tracked by AAAResearchReports.com. Free technical research on GALE, NVAX, ARIA, and MNKD can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ On Tuesday, shares in Galena Biopharma Inc. rallied to end the day at $3.88, which is 5.72% higher than the previous day's closing price of $3.67. The company's shares vacillated between $3.76 and $4.04 during the trading session. A total of 6.58 million shares were traded, which is above the daily average volume of 3.68 million. The company's shares have surged 73.99% in the last one month and 63.71% in the previous three months, outperforming the S&P 500, which has gained 2.44% and 8.81% during the respective periods. Moreover, Galena Biopharma Inc.'s stock is trading above its 50-day and 200-day moving averages of $2.38 and $2.21, respectively. Sign up and read the complimentary report on GALE at:] http://www.AAAResearchReports.com/GALE112713.pdf Novavax Inc.'s stock edged higher on Tuesday, tracking gains in the broader market. The company's shares closed the day 0.58% higher at $3.44, after trading between $3.38 and $3.47. A total of 2.93 million shares were traded, which is below the daily average volume of 3.10 million. The company's shares have gained 19.44% in the last one month and 13.16% in the previous three months, outperforming the S&P 500, which has advanced 2.44% and 8.81% during the respective periods. Additionally, Novavax Inc.'s stock is trading above its 50-day and 200-day moving averages of $3.06 and $2.52, respectively. The free report on NVAX can be downloaded by signing up now at: http://www.AAAResearchReports.com/NVAX112713.pdf On Tuesday, Ariad Pharmaceuticals Inc.'s stock plummeted to finish at $4.68, down 8.79% from the prior day's closing price of $5.13. The company's shares fluctuated between $4.56 and $5.62 during the trading session. A total of 78.75 million shares were traded, which is above the daily average volume of 14.37 million. Despite Tuesday's pullback, the company's shares have rallied 67.74% in the previous three trading sessions and 31.46% in the last one month, outperforming the S&P 500, which has gained 0.38% and 2.44% during the respective periods. Furthermore, Ariad Pharmaceuticals Inc.'s stock is trading below its 50-day and 200-day moving averages of $8.40 and $16.29, respectively. A free report on ARIA can be accessed by registering at: http://www.AAAResearchReports.com/ARIA112713.pdf Shares in MannKind Corp. oscillated between $4.98 and $5.04 before ending Tuesday's session 0.60% higher at $5.02. A total of 2.48 million shares were traded, which is below the daily average volume of 4.97 million. The company's shares have gained 0.60% in the previous three trading sessions, outperforming the S&P 500, which has gained 0.38% during the same period. However, MannKind Corp.'s stock is trading below its 50-day and 200-day moving averages of $5.26 and $5.32, respectively. Register with AAA Research Reports and download research on MNKD for free at: http://www.AAAResearchReports.com/MNKD112713.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID: email@example.com
Pre-Market Breakdown: Galena Biopharma Inc., Novavax Inc., Ariad Pharma Inc., and MannKind Corp.